Applied Research Systems Ars Holding N.v.

Surface Oncology, Inc.

Genzyme Corporation

Erasmus University Medical Center

Diacrin, Inc.

Novartis Ag

Adimab, LLC

Laboratoires Serono S.a.

Integrated Genetics, Inc.

Scott C. Chappel

Noreen P. Nugent

Christie A. Kelton

Scott C Chappel

Pamela M Holland

Andrew Lake

Bianka Prinz

Jonathan Hill

Edward G Bernstine

Matthew Rausch

Robert K Campbell

Christie Ann Kelton

Noreen P Nugent

Alison Paterson

Michael Warren

Bradford A Jameson

Frank Grosveld

Nels P Nielson

Michael N Gladstone

Christine Miller

Austin Dulak

Erik Devereaux

Tauqeer Zaidi

Sonia Das

Devapregasan Moodley

Kerry White

Jing Hua

Jerry M Thomas

Ansgar Brock

Wei Shu

Gege Tan

John Delmas Venable

Rachel W O'Connor

Dirksen Bussiere

Mikias Woldegiorgis

Alison M O'Neill

Christie A Kelton

The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Anti-IL-27 antibodies and uses thereof

The invention provides anti-CD39 antibody compositions and their use in treating cancer.

Anti-CD39 antibody compositions and methods

Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.

Antibody molecules to CD73 and uses thereof

The present disclosure relates to anti-CD39 antibodies, and antigen binding portions thereof and their use in treating cancer.

Antibodies that bind CD39 and uses thereof

Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.

Anti-CD47 antibodies and methods of use

A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&#x3b2; and TPO, linked to &#x3b1; subunit of a natural heterodimeric scaffold. Each coexpressed sequence contains a corresponding subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.

Homogeneity and secretion of a recombinant follicle stimulating hormone (FSH) in mammalian systems

A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr; and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.

Hybrid heterodimeric protein hormone comprising a TNF binding protein and a glycoprotein hormone subunit and method of using same

The invention relates to the use of human growth hormone for the manufacture of a medicament for stimulating hematopoiesis and immune reconstitution to be administered to a patient in need thereof about 30 days post-transplantation of hematopoietic stem cells.

Human growth hormone to stimulate hematopoiesis and immune reconstitution after hematopoietic stem cell transplantation in humans

A hybrid protein includes two coexpressed amino acid sequences forming a dimer. Each sequence contains the binding portion of a receptor, such as TBP1 or TBP2, or a ligand, such as IL-6, IFN-&bgr;and TPO, linked to a subunit of a heterodimeric proteinaceous hormone, such as hCG. Each coexpressed sequence contains a corresponding hormone subunit so as to form a heterodimer upon expression. Corresponding DNA molecules, expression vectors and host cells are also disclosed as are pharmaceutical compositions and a method of producing such proteins.

DNA encoding a hybrid heterodimeric protein

Hybrid heterodimeric protein hormone

Cells suitable for transplantation which have at least two different epitopes on a surface antigen altered prior to transplantation to inhibit rejection of the cells following transplantation into an allogeneic or xenogeneic recipient are disclosed. These cells are more successfully transplanted than cells which have only a single epitope on the surface antigen altered. Preferably, the antigen on the cell surface which is altered is an MHC class I antigen. Two different epitopes on an MHC class I antigen can be altered by contacting the cell with two molecules, such as antibodies or fragments thereof (e.g., F(ab').sub.2 fragments), which bind to two different epitopes on the antigen. Preferred epitopes on human MHC class I antigens to be altered are epitopes recognized by the monoclonal antibodies W6/32 and PT85. Improved methods for transplantation utilizing cells which have at least two different epitopes on a surface antigen altered prior to transplantation are also disclosed.

Cells with multiple altered epitopes on a surface antigen for use in

Growing community of inventors

Boston, MA, United States of America

Scott C Chappel